In a landmark study published inScience(2014), CRISPR/Cas9 was used to excise a defective exon from the dystrophin gene in a mouse model of DMD, leading to the expression of a shortened but functional dystrophin protein. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.